Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,612.89
    -1,673.61 (-3.33%)
     
  • CMC Crypto 200

    1,261.13
    -96.88 (-7.13%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

My 3 Favorite Under-the-Radar Healthcare Stocks for 2022

Looking for investment opportunities in the healthcare sector, and particularly in the biotechnology industry, can be overwhelming if you're not intimately familiar with the space. Here are three companies that operate surprisingly diverse operations -- either through drug pipeline variety, customer diversification, or differentiated product verticals -- offering a safety net, as well as prospects for growth, to their shareholders as a result. Led by its mission "to help people access, understand, and benefit from the human genome," 23andMe Holding (NASDAQ: ME) has quietly identified over 40 therapeutic programs from its treasure trove of genetic data.